Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Investigators study Pioglitazone and Vitamin E for treatment of NASH

A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.

29 Apr 2010

FDHN announces 2010 AGA Research Scholars

The Foundation for Digestive Health and Nutrition has announced the 2010 American Gastroenterological Association Foundation research scholars. The grants have been awarded to seven outstanding young gastroenterologists who promise to make significant strides in the field of gastrointestinal research.

28 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

IBS patients treated with cognitive behavior therapy have positive response: Study

A significant proportion of irritable bowel syndrome patients treated with cognitive behavior therapy have a positive response within four weeks of treatment, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

27 Apr 2010

Cellvizio probe-based confocal laser endomicroscopy to be featured at DDW 2010 conference

Mauna Kea Technologies, Inc., a leader in the in vivo cellular imaging market, announced that Cellvizio probe-based confocal laser endomicroscopy will be featured in key presentations at the annual Digestive Disease Week 2010 conference taking place in New Orleans May 1st thru the 5th.

27 Apr 2010

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Cumberland Pharmaceuticals Inc. today announced that results from a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, will be presented at the 2010 Digestive Disease Week meeting in New Orleans.

27 Apr 2010

Nitration and allergy

Food proteins are nitrated through various processes. Just how these processes affect food allergies, however, is only now coming to light. The latest findings of a research project funded by the Austrian Science Fund FWF are being presented today at an international symposium in Italy. The findings show that in the case of a particular food protein the nitrated form can trigger a stronger allergic reaction than the non-nitrated form. At the same time, however, this nitrated form of the protein is better digested and therefore rendered "harmless".

27 Apr 2010

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics.

26 Apr 2010

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Cytovance Biologics, LLC and Selexys Pharmaceutical Corporation jointly announce an agreement and execution of a Biopharmaceutical Development and Manufacturing collaboration for their Anti-PSGL-1 therapeutic agent. This monoclonal antibody (mAb) is being developed for treatment of inflammation associated with Crohn's disease as a lead indication.

26 Apr 2010

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Napo Pharmaceuticals, Inc., which focuses on the development and commercialization of proprietary pharmaceuticals for the treatment of diarrheal diseases in the global marketplace in collaboration with local partners, is pleased to announce the formation of a Finder's Agreement with its licensee for crofelemer in China, Luye Pharma Group Ltd. (formerly Asiapharm).

26 Apr 2010

Nycomed, Merck enter co-promotion agreement for Daxas in Canada and Europe

Nycomed and Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). In addition, the two companies have signed an exclusive distribution agreement for the commercialization of Daxas® in the United Kingdom.

26 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

COX-2 expression not an adequate independent prognostic factor: Research

Cyclooxygenase-2 represents a key modulatory molecule in inflammation and carcinogenesis. COX-2 is known to have multiple tumorigenic effects. Increased expression of COX-2 has been observed in a variety of tumors including pancreatic cancer.

22 Apr 2010

Study analyzes effects of untimely and sudden parental death on childhood development

Losing a parent to suicide makes children more likely to die by suicide themselves and increases their risk of developing a range of major psychiatric disorders, according to a study led by Johns Hopkins Children's Center that is believed to be the largest one to date on the subject.

22 Apr 2010

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.

22 Apr 2010

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Salix Pharmaceuticals, Ltd. today announced that the Company will host a DDW2010 Investor Event on Monday, May 3 2010 from 9:00 p.m. to 10:00 p.m. Central Time (10:00 p.m. to 11:00 p.m. ET).

22 Apr 2010

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Abbott today announced financial results for the first quarter ended March 31, 2010.

21 Apr 2010

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Investigators study Pioglitazone and Vitamin E for treatment of NASH

FDHN announces 2010 AGA Research Scholars

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

IBS patients treated with cognitive behavior therapy have positive response: Study

Cellvizio probe-based confocal laser endomicroscopy to be featured at DDW 2010 conference

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Nitration and allergy

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Nycomed, Merck enter co-promotion agreement for Daxas in Canada and Europe

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

COX-2 expression not an adequate independent prognostic factor: Research

Study analyzes effects of untimely and sudden parental death on childhood development

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in